Understand the source comparison
How to Use Peptides for Psoriasis: Peptide Comparison for Psoriasis Research
Before initiating any peptide protocol, understanding mechanism-specific differences determines which compound addresses your research question. Thymosin Alpha-1 Treg differentiation, IL-2R upregulation 1.6mg twice weekly ~2 hours CD4+ T-regulatory cells Best
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before initiating any peptide protocol, understanding mechanism-specific differences determines which compound addresses your research question.
- Thymosin Alpha-1
- Treg differentiation, IL-2R upregulation
- 1.6mg twice weekly
- ~2 hours
- CD4+ T-regulatory cells
- Best for psoriasis cases with documented Treg deficiency or autoimmune comorbidity. Requires sustained 12+ week protocols
- KPV Tripeptide
- NF-kB inhibition, cytokine transcription suppression
- 500mcg–2mg daily
- 4–6 hours
- Nuclear inflammatory signaling
- Targets acute flare cytokine cascades. Most effective during active inflammation, less impact in remission phases
- BPC-157
- Epithelial repair, angiogenesis modulation
- 250–500mcg twice daily
- Keratinocyte proliferation, wound healing
- Addresses tissue-level plaque burden, not immune root cause. Adjunct to immunomodulatory peptides, not standalone
- LL-37 (Cathelicidin)
- Antimicrobial peptide, immune signaling
- Topical or 100–500mcg injection
- Variable
- Keratinocyte activation, TLR signaling
- Under investigation for guttate psoriasis triggered by bacterial antigens. Mechanism distinct from plaque psoriasis